DBP International AB: positive response for SI-053 from the Federal Institute for Drugs and Medical Devices in Germany has been received
Double Bond Pharmaceutical International AB (publ) ("DBP") is about to take a very important step towards the start of clinical trial phase 1 in Germany of its front-line product SI-053 in patients with glioblastoma – a positive response from Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte) in Germany has now been received. Germany is the second country to approve the start of the phase 1 clinical trial; a positive response from Ethical Committee in the Netherlands was received in September 2021